BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2023-12
297 industry Phase 2/3 trial readout(s) and 28 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2023-12 est. | P2 | Longeveron Inc. LGVN | NCT02587572 Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial | Metabolic Disease; Endothelial Dysfunction | withdrawn | |
| 2023-12 | P2 | Prokidney PROK | NCT02836574 A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease | Type 2 Diabetes Mellitus; Chronic Kidney Disease | completed | 83 |
| 2023-12 est. | P3 | Ablative Solutions, Inc. | NCT02910414 TARGET BP I Clinical Trial | Hypertension | active not recruiting | 300 |
| 2023-12 est. | P1/P2 | Healeon Medical Inc | NCT02987855 Adipose Stem/Stromal Cells in RSD, CRPS, Fibromyalgia | RSD (Reflex Sympathetic Dystrophy); CRPS - Complex Regional Pain Syndrome Type I; Fibromyalgia | withdrawn | |
| 2023-12 est. | P3 | Nutricia Research | NCT03062995 A Clinical Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on the Development of Allergic Manifestations in Infan | Immunity | withdrawn | |
| 2023-12 est. | P2 | Infan Industria Quimica Farmaceutica Nacional | NCT03084952 Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients | Leishmaniasis; American, Cutaneous; Drug Side Effect | unknown | 52 |
| 2023-12 est. | P2 | Zydus Therapeutics Inc. | NCT03097107 Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL | Dyslipidemias | suspended | 124 |
| 2023-12 est. | P3 | Sequential Medicine Ltd | NCT03338764 An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia | Transient Insomnia | withdrawn | |
| 2023-12 est. | P3 | Symphogen A/S | NCT03717038 Sym004 Versus TAS-102 in Patients With mCRC | Metastatic Colorectal Cancer; Colorectal Cancer Metastatic; Carcinoma | withdrawn | |
| 2023-12 est. | P3 | Biocad | NCT03912389 Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC | Non-Squamous Non-Small Cell Neoplasm of Lung | unknown | 292 |
| 2023-12 est. | P1/P2 | Actinium Pharmaceuticals ATNM | NCT03932318 Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | Acute Myeloid Leukemia; Relapsed Adult AML | withdrawn | |
| 2023-12 est. | P2 | GeneOne Life Science, Inc. | NCT04060316 GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery | Sinusitis Chronic | unknown | 99 |
| 2023-12 est. | P3 | Applied Therapeutics, Inc. AMAT | NCT04083339 Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy | Diabetic Cardiomyopathies | active not recruiting | 675 |
| 2023-12 est. | P2 | VistaGen Therapeutics, Inc. VTGN | NCT04147949 AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia | Parkinson Disease; Dyskinesia, Medication-Induced; L-Dopa Causing Adverse Effects in Therapeutic Use | unknown | 20 |
| 2023-12 est. | P3 | Infectopharm Arzneimittel GmbH | NCT04398758 Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood | Atopic Dermatitis; Infant, Newborn | unknown | 360 |
| 2023-12 est. | P3 | Asieris MediTech (Hong Kong) Co., Ltd. | NCT04484415 Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL) | Cervical Intraepithelial Neoplasia Grade 2/3 | unknown | 402 |
| 2023-12 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT04503902 Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | unknown | 46 |
| 2023-12 est. | P2 | AB Science | NCT04622865 Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 | SARS-CoV 2; COVID-19; Coronavirus Disease 2019 | unknown | 200 |
| 2023-12 est. | P3 | Hamad Medical Corporation | NCT04654507 Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children | Urinary Tract Infections in Children; Dexamethasone; Kidney Scarring; Acute Pyelonephritis; Hyperten | unknown | 120 |
| 2023-12 est. | P1/P2 | ASC Therapeutics | NCT04676048 ASC618 Gene Therapy in Hemophilia A Patients | Hemophilia A | recruiting | 12 |
| 2023-12 est. | P2 | ES Therapeutics Australia Pty Ltd | NCT04714996 Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy | Drug Resistant Epilepsy | unknown | 24 |
| 2023-12 est. | P2 | Biosolution Co., Ltd. | NCT04744402 Phase 2 Clinical Trial of CartiLife® in the United States | Articular Cartilage Defect; Articular Cartilage Degeneration | recruiting | 25 |
| 2023-12 est. | P1/P2 | Elpiscience Biopharma, Ltd. | NCT04841538 A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors | Thoracic Tumors; Non-small Cell Lung Cancer; Small Cell Lung Cancer | withdrawn | |
| 2023-12 est. | P2/P3 | ProQR Therapeutics PRQR | NCT04855045 An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) Wi | Leber Congenital Amaurosis 10; Blindness; Leber Congenital Amaurosis; Vision Disorders; Sensation Di | unknown | 15 |
| 2023-12 est. | P2 | Emerald Health Pharmaceuticals | NCT04909502 Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis | suspended | 50 |
| 2023-12 est. | P2 | Phoenicis Therapeutics | NCT05020730 Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa | Hidradenitis Suppurativa | unknown | 50 |
| 2023-12 est. | P2 | EMS | NCT05031481 Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis. | Vulvovaginal Candidiasis | withdrawn | |
| 2023-12 est. | P2 | AB Science | NCT05047783 Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 | Covid19; SARS-CoV2 Infection; Coronavirus Disease 2019 | unknown | 78 |
| 2023-12 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05054842 Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes | Type 2 Diabetes | unknown | 174 |
| 2023-12 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05068206 A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus Cape | Unresectable Metastatic Colorectal Cancer | unknown | 120 |
| 2023-12 est. | P1/P2 | National Vaccine and Serum Institute, China | NCT05069129 Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Age | COVID-19 Pneumonia; Coronavirus Infections | unknown | 1848 |
| 2023-12 est. | P2 | Shanghai Miracogen Inc. | NCT05141747 A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. | Locally Advanced Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer | unknown | 60 |
| 2023-12 est. | P2 | Shanghai Miracogen Inc. | NCT05141786 A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). | Non-small- Cell Lung Cancer (NSCLC) | unknown | 100 |
| 2023-12 est. | P1/P2 | ChitogenX Inc | NCT05333211 Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R® | Rotator Cuff Tears | unknown | 78 |
| 2023-12 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05346952 A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatmen | Advanced Non-squamous Non-small Cell Lung Cancer | unknown | 390 |
| 2023-12 est. | P2/P3 | Yantai Patronus Biotech Co., Ltd. | NCT05602558 The Phase Ⅱ/Ⅲ Trial of LYB001 | COVID-19 | unknown | 18000 |
| 2023-12 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05645315 Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors | Advanced Solid Tumor | unknown | 127 |
| 2023-12 est. | P2 | Bioxytran Inc. BIXT | NCT05733780 To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M | COVID-19; SARS CoV 2 Infection | unknown | 40 |
| 2023-12 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05775575 A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer | Advanced Breast Cancer | unknown | 65 |
| 2023-12 est. | P2 | Innovo Therapeutics, Inc. | NCT05838833 Ointment to Prevent Scar After Thyroidectomy | Scar | unknown | 75 |
| 2023-12 est. | P2 | Beijing Tide Pharmaceutical Co., Ltd | NCT05950152 Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery | Pain, Post-operative | unknown | 108 |
| 2023-12 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06047483 A Trial of HRF2105 Patch in Relieving Pain of Osteoarthritis | Analgesia and Anti-inflammatory of Osteoarthritis | unknown | 90 |
| 2023-12-01 | P2 | CUTISS AG | NCT03394612 Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children | Skin Wound | completed | 21 |
| 2023-12-01 est. | P2 | Jubilant DraxImage Inc. | NCT03561259 A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects | Neuroblastoma; Neuroectodermal Tumors; Neoplasms | unknown | 60 |
| 2023-12-01 est. | P3 | Anji Pharma | NCT04854512 Investigational Study of Delayed Release Metformin | Diabetes Mellitus, Type 2 | suspended | 675 |
| 2023-12-01 est. | P1/P2 | Beijing Immunochina Medical Science & Technology Co., Ltd. | NCT05117138 Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | Melanoma; Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma | unknown | 39 |
| 2023-12-04 | P3 | Cerus Corporation CERS | NCT03459287 Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients | Anemia | completed | 581 |
| 2023-12-04 est. | P2 | ViGenCell Inc. | NCT03671850 VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients | Extranodal NK/T-cell Lymphoma | unknown | 48 |
| 2023-12-04 | P2 | Beijing Continent Pharmaceutical Co, Ltd. | NCT03902509 A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury. | Radiation-induced Lung Injury | completed | 126 |
| 2023-12-04 | P2 | Janssen Research & Development, LLC | NCT04083976 A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations | Advanced Solid Tumor | completed | 316 |
| 2023-12-04 | P2 | Aribio Lab Co., Ltd. | NCT04289987 A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine | Hepatitis B, Chronic | completed | 134 |
| 2023-12-04 | P2 | Genentech, Inc. | NCT04632992 A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Respo | Advanced Unresectable or Metastatic Solid Malignancy | completed | 252 |
| 2023-12-04 | P3 | Annovis Bio Inc. ANVS | NCT05357989 A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD | Parkinson's Disease, Idiopathic | completed | 523 |
| 2023-12-04 | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05475717 A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI | Contrast-induced Acute Kidney Injury | terminated | 132 |
| 2023-12-04 | P2 | Larimar Therapeutics, Inc. LRMR | NCT05579691 A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia | Friedreich Ataxia | completed | 28 |
| 2023-12-04 | P3 | Keymed Biosciences Co.Ltd | NCT05908032 Study of CM310 in Subjects With Allergic Rhinitis | Allergic Rhinitis | completed | 108 |
| 2023-12-04 | P3 | Daewon Pharmaceutical Co., Ltd. | NCT07076056 Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 | Type 2 Diabetes | completed | 230 |
| 2023-12-05 | P1/P2 | Spark Therapeutics, Inc. SPKLF | NCT03003533 A Gene Transfer Study for Hemophilia A | Hemophilia A | completed | 25 |
| 2023-12-05 | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT05107011 Phase I/II Clinical Trial of LBL-015 for Injection | Advanced Malignant Tumor | completed | 25 |
| 2023-12-05 | P2 | Jazz Pharmaceuticals JAZZ | NCT05178316 A Study of JZP150 in Adults With Posttraumatic Stress Disorder | Post Traumatic Stress Disorder | completed | 282 |
| 2023-12-05 | P2 | Daewoong Pharmaceutical Co. LTD. | NCT05378360 DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities | Rash Acneiform | completed | 96 |
| 2023-12-05 | P3 | Taisho Pharmaceutical Co., Ltd. | NCT05453136 Phase III Study of TS-142 in Patients with Insomnia | Patients with Insomnia | completed | 1155 |
| 2023-12-05 | P2 | Beijing Suncadia Pharmaceuticals Co., Ltd | NCT05690711 A Trial of HRS8179 on Brain Swelling After Large Hemispheric Infarction | Brain Swelling, Large Hemispheric Infarction | completed | 40 |
| 2023-12-05 est. | P1/P2 | Pure Green Pharmaceuticals Inc. PURE | NCT05766969 Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA | Diabetic Peripheral Neuropathic Pain | unknown | 52 |
| 2023-12-05 | P2 | Shandong New Time Pharmaceutical Co., LTD | NCT06226350 A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma | Cervical Cancer | completed | 29 |
| 2023-12-06 | P1/P2 | NantPharma, LLC | NCT03127124 QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer | Pancreatic Adenocarcinoma Metastatic | withdrawn | |
| 2023-12-06 | P3 | Millennium Pharmaceuticals, Inc. MGIH | NCT03748953 Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantatio | Multiple Myeloma | completed | 37 |
| 2023-12-06 | P1/P2 | Aposcience AG | NCT04277598 A Study to Evaluate Safety and Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer | Diabetic Foot Ulcer (DFU) | completed | 159 |
| 2023-12-06 | P1/P2 | Entos Pharmaceuticals Inc. | NCT04591184 A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults | SARS-CoV-2 | completed | 268 |
| 2023-12-06 | P2 | Bristol-Myers Squibb BMY | NCT05169684 A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | terminated | 10 |
| 2023-12-06 | P2 | BioLite, Inc. | NCT05202327 PDC-1421 Treatment in Adult Patients With ADHD | Attention-Deficit Hyperactivity Disorder (ADHD) | completed | 99 |
| 2023-12-06 | P2 | Aclaris Therapeutics, Inc. ACRS | NCT05511519 Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis | Psoriatic Arthritis | terminated | 47 |
| 2023-12-06 | P2 | Janssen Research & Development, LLC | NCT05564052 A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | Lymphoma, Mantle-Cell | completed | 36 |
| 2023-12-06 | P3 | GlaxoSmithKline | NCT05879107 Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) I | Respiratory Syncytial Virus Infections | completed | 1113 |
| 2023-12-06 | P2 | Zhejiang Echon Biopharm Limited | NCT06429566 Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous Ulcers | Healthy | unknown | 120 |
| 2023-12-07 | P1/P2 | BeiGene | NCT04276493 Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | Breast Cancer; Gastric Cancer; Gastroesophageal Junction Cancer | completed | 71 |
| 2023-12-07 | P2 | Pfizer PFE | NCT04996004 A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | Leiomyosarcoma | terminated | 76 |
| 2023-12-07 | P2 | Dreamhawk Vision Biotech, Inc. | NCT05486728 Phase II Study of SHJ002 Sterile Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease | Dry Eye Disease | completed | 85 |
| 2023-12-08 | P2 | Palatin Technologies, Inc PTN | NCT04318145 Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects | Heart Failure With Preserved Ejection Fraction | terminated | 15 |
| 2023-12-08 | P2 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | NCT04764448 A Study of Belcesiran in Patients With AATLD | Alpha 1-Antitrypsin Deficiency | terminated | 16 |
| 2023-12-08 | P3 | Jiangsu Simcere Pharmaceutical Co., Ltd. | NCT04908787 A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | Ovarian Cancer | completed | 421 |
| 2023-12-08 | P3 | Novartis Pharmaceuticals NVS | NCT05048342 A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines | Chronic Spontaneous Urticaria | completed | 71 |
| 2023-12-08 | P2 | Novartis Pharmaceuticals NVS | NCT05114746 Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan | Prostate Cancer | completed | 94 |
| 2023-12-10 | P2 | Taiwan Bio Therapeutics Inc. | NCT05027581 Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA) | Osteoarthritis, Knee | completed | 72 |
| 2023-12-10 | P2 | Keymed Biosciences Co.Ltd | NCT05908721 Study of CM310 in Patients With Allergic Rhinitis | Allergic Rhinitis | completed | 100 |
| 2023-12-10 est. | P2 | Sinocelltech Ltd. | NCT05933512 A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines | COVID-19; SARS-CoV-2 Infection | unknown | 600 |
| 2023-12-11 | P3 | Novartis Pharmaceuticals NVS | NCT03439046 Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a | Breast Cancer | terminated | 287 |
| 2023-12-11 | P2 | Kadmon, a Sanofi Company | NCT03640481 Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy | Chronic Graft-versus-host-disease | terminated | 159 |
| 2023-12-11 | P2 | Eli Lilly and Company LLY | NCT04166773 A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | completed | 190 |
| 2023-12-11 | P1/P2 | Precirix | NCT04467515 A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2- | Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Pro | terminated | 13 |
| 2023-12-11 | P3 | Sylentis, S.A. | NCT04819269 Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome | Dry Eye Disease; Sjögren Syndrome | completed | 203 |
| 2023-12-11 | P2 | Alnylam Pharmaceuticals ALNY | NCT05103332 Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | Hypertension | completed | 663 |
| 2023-12-11 | P3 | Hanmi Pharmaceutical Company Limited HAFC | NCT05450601 A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients | Hypertension | completed | 249 |
| 2023-12-11 | P2 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | NCT05760703 Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B | Chronic Hepatitis b | terminated | 9 |
| 2023-12-11 | P2 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | NCT05760781 To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B | Chronic Hepatitis b | terminated | 9 |
| 2023-12-11 | P3 | CanSino Biologics Inc. | NCT06011200 A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population | Epidemic Meningitis | completed | 1000 |
| 2023-12-12 | P2 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT02375620 Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature | Short Stature Children Born Small for Gestational Age (SGA) | active not recruiting | 96 |
| 2023-12-12 | P1/P2 | HUYABIO International, LLC. | NCT02718066 Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | Melanoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer | completed | 96 |
| 2023-12-12 | P3 | Bristol-Myers Squibb BMY | NCT04340193 A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Live | Cancer, Hepatocellular | completed | 26 |
| 2023-12-12 | P3 | Ferring Pharmaceuticals | NCT04773353 Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian Women | Infertility | completed | 220 |
| 2023-12-12 | P3 | Merck Sharp & Dohme LLC MRK | NCT05119855 Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory S | Papillomavirus Infections; Coronavirus Disease (COVID-19) | completed | 165 |
| 2023-12-12 | P2 | Janssen Research & Development, LLC | NCT05275023 An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Ch | Hepatitis B, Chronic | completed | 37 |
| 2023-12-12 | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT05661734 A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain | Pain | completed | 258 |
| 2023-12-13 | P3 | Shire | NCT03283085 A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) | Crohn's Disease; Ulcerative Colitis | completed | 557 |
| 2023-12-13 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04956432 A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout | Gout | completed | 779 |
| 2023-12-13 | P2 | Regeneron Pharmaceuticals REGN | NCT05088460 A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) | Familial Partial Lipodystrophy; Metabolic Abnormalities | terminated | 20 |
| 2023-12-13 | P3 | Novo Nordisk A/S NVO | NCT05259033 A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People | Diabetes Mellitus, Type 2 | completed | 683 |
| 2023-12-13 | P2 | EmpowerPharm Inc. | NCT05600114 Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder | Social Anxiety Disorder | completed | 239 |
| 2023-12-13 | P2 | Takeda TAK | NCT05687916 A Study of TAK-861 in Participants With Narcolepsy Type 2 | Narcolepsy Type 2 | completed | 71 |
| 2023-12-14 | P2 | MAPS Europe B.V. | NCT04030169 Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study | PTSD | completed | 21 |
| 2023-12-14 | P2 | HI-Bio, A Biogen Company | NCT04733040 Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) | Glomerulonephritis; Membranous Nephropathy; antiPLA2R Positive | completed | 24 |
| 2023-12-14 est. | P2 | BioSight Ltd. | NCT04749355 Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS | AML, Adult; MDS; Relapse/Recurrence; Refractory Acute Myeloid Leukemia | unknown | 40 |
| 2023-12-14 | P2 | Merck Sharp & Dohme LLC MRK | NCT04875195 A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lym | Hodgkin's Lymphoma; Primary Mediastinal Large B-cell Lymphoma (PMBCL) | completed | 66 |
| 2023-12-14 | P2/P3 | Reneo Pharma Ltd | NCT05267574 An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead) | Primary Mitochondrial Myopathy | terminated | 155 |
| 2023-12-14 | P3 | mAbxience Research S.L. | NCT05338086 A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis. | Postmenopausal Women With Osteoporosis | completed | 558 |
| 2023-12-14 | P3 | Biopharma Plasma LLC | NCT05422365 Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults | Primary Immune Thrombocytopenia | completed | 32 |
| 2023-12-14 | P2 | Takeda TAK | NCT05687903 A Study of TAK-861 in Participants With Narcolepsy Type 1 | Narcolepsy Type 1 | completed | 112 |
| 2023-12-14 | P2 | Suzhou Kintor Pharmaceutical Inc, | NCT06692465 To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males | Alopecia; Male Pattern Hair Loss | completed | 180 |
| 2023-12-15 | P2 | Celgene | NCT03484702 Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkin | completed | 113 |
| 2023-12-15 | P1/P2 | TJ Biopharma Co., Ltd. | NCT04202003 A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With | Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes(MDS) | completed | 105 |
| 2023-12-15 | P3 | Incyte Corporation INCY | NCT04205812 Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | Metastatic Squamous Non-Small Cell Lung Cancer; Metastatic Nonsquamous Non-Small Cell Lung Cancer | completed | 583 |
| 2023-12-15 est. | P2/P3 | Biomed Industries, Inc. | NCT04452565 NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection | Coronavirus Infection; Severe Acute Respiratory Infection; Severe Acute Respiratory Syndrome Coronav | unknown | 525 |
| 2023-12-15 | P2 | Akero Therapeutics, Inc | NCT05039450 A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry) | NASH - Nonalcoholic Steatohepatitis | completed | 213 |
| 2023-12-15 est. | P2 | Shanghai Henlius Biotech | NCT05290220 HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | unknown | 60 |
| 2023-12-15 | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT05553366 Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | Acute Pain | completed | 1075 |
| 2023-12-15 est. | P2 | Samus Therapeutics, Inc. | NCT05612633 A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN | Accelerated Phase MPN; Blast Phase MPN | withdrawn | |
| 2023-12-15 | P2 | Chong Kun Dang Pharmaceutical | NCT05677438 A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia | Androgenetic Alopecia | completed | 121 |
| 2023-12-15 | P2 | Okyo Pharma Ltd OKYO | NCT05759208 The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease | Dry Eye Disease | completed | 240 |
| 2023-12-15 | P2 | MiMedx Group, Inc. MDXG | NCT05796765 Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis | Knee Osteoarthritis | terminated | 43 |
| 2023-12-16 est. | P2 | Phagenix | NCT05369104 Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus Aureus Treated With DAIR. | Infection of Total Hip Joint Prosthesis; Infection of Total Knee Joint Prosthesis | unknown | 64 |
| 2023-12-17 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT04151563 A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Ch | Carcinoma, Non-small Cell Lung Cancer | withdrawn | |
| 2023-12-17 | P1/P2 | Triumvira Immunologics, Inc. | NCT04727151 TAC T-cells for the Treatment of HER2-positive Solid Tumors | HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer | terminated | 28 |
| 2023-12-17 | P3 | Shanghai Henlius Biotech | NCT05352516 A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture | Postmenopausal | completed | 514 |
| 2023-12-18 | P2 | Merck Sharp & Dohme LLC MRK | NCT04218851 Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104) | Invasive Aspergillosis | completed | 31 |
| 2023-12-18 | P2 | Vivoryon Therapeutics N.V. | NCT04498650 A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD | Early Alzheimers Disease; Mild Cognitive Impairment Due to AD | completed | 259 |
| 2023-12-18 | P2 | Lipocine Inc. LPCN | NCT04874350 A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia | Liver Cirrhosis; Sarcopenia | completed | 30 |
| 2023-12-18 | P3 | Novartis Pharmaceuticals NVS | NCT05032157 A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines | Chronic Spontaneous Urticaria | completed | 455 |
| 2023-12-18 | P2 | Allakos Inc. | NCT05155085 A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis | Atopic Dermatitis | terminated | 131 |
| 2023-12-18 | P2 | TrueBinding, Inc. | NCT05156827 A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke | Acute Ischemic Stroke | withdrawn | |
| 2023-12-18 | P2 | Sensorion | NCT05258773 Evaluation of the Presence of SENS-401 in the Perilymph | Hearing Loss | completed | 28 |
| 2023-12-18 | P3 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT05881785 Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis | Axial Spondyloarthritis | completed | 465 |
| 2023-12-19 | P1/P2 | Amytrx Therapeutics, Inc. | NCT04313400 Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis | Atopic Dermatitis | completed | 91 |
| 2023-12-19 | P2 | Celgene | NCT04350463 A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers | Neoplasms | completed | 92 |
| 2023-12-19 | P1/P2 | Takeda TAK | NCT04501614 A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL); Ph+ Mixed Phenotyp | terminated | 11 |
| 2023-12-19 | P1/P2 | Allist Pharmaceuticals, Inc. | NCT04720976 JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | Solid Tumor; NSCLC | completed | 58 |
| 2023-12-19 | P2 | Pierre Fabre Medicament | NCT05004350 A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FO | BRAF V600E; Metastatic Colorectal Cancer | completed | 107 |
| 2023-12-19 | P1/P2 | Arcturus Therapeutics, Inc. ARCT | NCT05037097 A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults | COVID-19; SARS-CoV-2 Infection; Corona Virus Infection | completed | 72 |
| 2023-12-19 | P2 | Gilead Sciences GILD | NCT05052996 Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV | HIV-1 Infection | active not recruiting | 142 |
| 2023-12-19 | P1/P2 | LG Chem | NCT05237752 A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA | Osteoarthritis, Knee | completed | 74 |
| 2023-12-19 | P2 | Incyte Corporation INCY | NCT05247489 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo | Vitiligo | completed | 55 |
| 2023-12-19 | P2 | ModernaTX, Inc. | NCT05868382 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults | Influenza | completed | 270 |
| 2023-12-19 | P2 | Iacta Pharmaceuticals | NCT05992922 A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants | Dry Eye Syndromes | terminated | 40 |
| 2023-12-20 | P2 | Celgene | NCT03361748 Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma | Multiple Myeloma | completed | 149 |
| 2023-12-20 | P3 | Advicenne Pharma | NCT03644706 Study Evaluating Subjects With Distal Renal Tubular Acidosis | Distal Renal Tubular Acidosis | terminated | 3 |
| 2023-12-20 | P1/P2 | Teva Branded Pharmaceutical Products R&D LLC | NCT04157517 A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | Neoplasms; Melanoma | terminated | 45 |
| 2023-12-20 | P3 | CellSeed Inc. | NCT04689594 A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Es | Superficial Esophageal Cancer | terminated | 1 |
| 2023-12-20 | P3 | BeiGene | NCT04921358 Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | terminated | 377 |
| 2023-12-20 | P3 | InDex Pharmaceuticals | NCT04985968 The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis | Ulcerative Colitis | terminated | 171 |
| 2023-12-20 | P2 | CuraSen Therapeutics, Inc. | NCT05104463 A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease | Mild Cognitive Impairment; Dementia | completed | 64 |
| 2023-12-20 | P2 | Jazz Pharmaceuticals JAZZ | NCT05126433 Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; Urothelial Cancer; Poorly Differentiated Neuroendocrin | terminated | 47 |
| 2023-12-20 est. | P2 | Shanghai Henlius Biotech | NCT05246982 HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer | Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) | unknown | 40 |
| 2023-12-20 est. | P1/P2 | Shanghai Mabgeek Biotech.Co.Ltd | NCT05382910 A Study of MG-K10 in Subjects With Asthma | Asthma | unknown | 180 |
| 2023-12-20 | P2 | Merck Sharp & Dohme LLC MRK | NCT05446870 Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | High-grade Serous Ovarian Carcinoma; Ovarian Carcinoma | completed | 160 |
| 2023-12-20 | P2/P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05795621 A Study of IBI311 in Subjects With Active Thyroid Eye Disease | Thyroid Eye Disease | completed | 115 |
| 2023-12-20 | P2 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | NCT06439433 ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection | Cervical Intraepithelial Neoplasia Grade 2; Papillomavirus Infections; p16 Protein | completed | 119 |
| 2023-12-20 | P3 | Jecho Biopharmaceuticals Co., Ltd. | NCT07389577 A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) | Wet Age-related Macular Degeneration | completed | 443 |
| 2023-12-21 | P3 | Coherex Medical | NCT03302494 WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2 | Stroke | terminated | 248 |
| 2023-12-21 | P2 | Eisai Inc. | NCT03477175 Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai | Solid Tumors | completed | 40 |
| 2023-12-21 | P3 | Actelion | NCT04271475 A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | terminated | 127 |
| 2023-12-21 | P3 | Ocular Therapeutix, Inc. OCUL | NCT04539548 A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract | Cataract | completed | 65 |
| 2023-12-21 | P2 | Jazz Pharmaceuticals JAZZ | NCT04745026 Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder | Autism Spectrum Disorder | completed | 103 |
| 2023-12-21 | P1/P2 | Guangdong Raynovent Biotech Co., Ltd | NCT05119972 Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis (IPF) | completed | 15 |
| 2023-12-21 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT05759897 A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes Mellitus | Type 2 Diabetes | unknown | 180 |
| 2023-12-22 | P2 | SecuraBio | NCT03372057 A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Peripheral T-cell Lymphoma | completed | 156 |
| 2023-12-22 | P3 | Avadel | NCT04451668 An Open Label Study of FT218 in Subjects With Narcolepsy | Narcolepsy; Cataplexy; Excessive Daytime Somnolence; Sleep Disorder; Sleep Disturbance; Sleep Wake D | completed | 184 |
| 2023-12-22 | P2 | Taiho Pharmaceutical Co., Ltd. | NCT05335499 A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | completed | 126 |
| 2023-12-23 | P3 | Beijing Northland Biotech. Co., Ltd. | NCT04274049 Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2) | Arterial Occlusive Disease; Ischemia; Ulcers; Peripheral Vascular Disease | completed | 242 |
| 2023-12-23 | P2 | Golo | NCT05844631 The Effects of the GOLO for Life® Plan and Release Supplement on Weight Management in Overweight and Obese Adults | Obese; Overweight | completed | 83 |
| 2023-12-24 | P3 | TenNor Therapeutics (Suzhou) Limited | NCT05857163 Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection | H.Pylori Infection | completed | 700 |
| 2023-12-25 | P3 | Astellas Pharma Inc | NCT03182244 A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutat | AML With FLT3 Mutation | completed | 276 |
| 2023-12-25 | P3 | APRINOIA Therapeutics | NCT05542953 [18F]APN-1607 PET in Subjects With AD Compared to HC | Alzheimer's Disease; Mild Cognitive Impairment Due to Alzheimer's Disease; Healthy Volunteers | completed | 230 |
| 2023-12-25 | P1/P2 | BioNova Pharmaceuticals (Shanghai) LTD. | NCT05611853 Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | B-cell Lymphoma; Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle Ce | terminated | 9 |
| 2023-12-25 | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06091436 To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference | Infertility | completed | 176 |
| 2023-12-26 | P2 | CStone Pharmaceuticals | NCT05297890 A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer | Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer | active not recruiting | 70 |
| 2023-12-26 | P1/P2 | Suzhou Junjing BioSciences Co., Ltd. | NCT05326035 A Study of WJ05129 in Advanced Malignant Solid Tumors | Locally Advanced or Metastatic Malignant Solid Tumors | terminated | 26 |
| 2023-12-26 | P3 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05359068 Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension | Essential Hypertension | completed | 957 |
| 2023-12-26 | P2 | Taisho Pharmaceutical Co., Ltd. | NCT05699239 A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | Hyperphosphatemia Patients on Hemodialysis | completed | 326 |
| 2023-12-27 | P3 | Actelion | NCT03422328 A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan | Pulmonary Arterial Hypertension; Chronic Thromboembolic Pulmonary Hypertension | completed | 151 |
| 2023-12-27 | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT03797456 A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) | MZL | completed | 111 |
| 2023-12-27 | P1/P2 | Laekna Limited | NCT04060394 Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | Metastatic Castration-resistant Prostate Cancer | completed | 49 |
| 2023-12-27 | P3 | Novartis Pharmaceuticals NVS | NCT05030311 A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines | Chronic Spontaneous Urticaria | completed | 470 |
| 2023-12-27 | P3 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05051761 Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata | Alopecia Areata | completed | 425 |
| 2023-12-27 | P2 | Allakos Inc. | NCT05528861 A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | terminated | 127 |
| 2023-12-27 | P2 | Pliant Therapeutics, Inc. PLRX | NCT05621252 Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) | Idiopathic Pulmonary Fibrosis | completed | 10 |
| 2023-12-28 | P1/P2 | Forma Therapeutics, Inc. | NCT02719574 Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | Acute Myeloid Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndrome | completed | 336 |
| 2023-12-28 | P2/P3 | Novartis Pharmaceuticals NVS | NCT03217422 ADCC Mediated B-Cell dEpletion and BAFF-R Blockade | Autoimmune Hepatitis | completed | 68 |
| 2023-12-28 | P3 | Baxalta now part of Shire | NCT03393975 A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) | Thrombotic Thrombocytopenic Purpura (TTP) | completed | 52 |
| 2023-12-28 | P1/P2 | ImmunoGen, Inc. | NCT04622774 First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors | Advanced Solid Tumor | completed | 56 |
| 2023-12-28 | P3 | Takeda TAK | NCT04668157 A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure | Hypertension | completed | 10 |
| 2023-12-28 | P2/P3 | HilleVax | NCT05281094 Efficacy and Safety of Two Doses of HIL-214 in Children | Gastroenteritis | terminated | 3084 |
| 2023-12-28 | P2 | Modern Biosciences Ltd MDRN | NCT05460832 Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA | Rheumatoid Arthritis | completed | 248 |
| 2023-12-28 | P2/P3 | Yisheng Biopharma (Singapore) Pte. Ltd. | NCT05463419 A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose. | Covid-19 Vaccine | completed | 5860 |
| 2023-12-28 | P2 | BioNTech SE BNTX | NCT05596734 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza | Influenza, Human; COVID-19 | completed | 1019 |
| 2023-12-28 | P2 | Clinuvel Pharmaceuticals Limited CUVL | NCT05854784 Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP) | Variegate Porphyria | completed | 6 |
| 2023-12-29 | P2/P3 | Serum Institute of India Pvt. Ltd. | NCT03152903 Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence | Prevention of TB Recurrence | completed | 2000 |
| 2023-12-29 | P1/P2 | GeoVax, Inc. GOVX | NCT03754933 Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer | Recurrent Head and Neck Cancer | completed | 10 |
| 2023-12-29 | P3 | Novartis Pharmaceuticals NVS | NCT03785405 Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF | Heart Failure | completed | 216 |
| 2023-12-29 | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT04721223 JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | Advanced Solid Tumor; Esophageal Squamous Cell Carcinoma; Non Small Cell Lung Cancer; Head and Neck | completed | 12 |
| 2023-12-29 | P2 | Eli Lilly and Company LLY | NCT05123586 A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | terminated | 85 |
| 2023-12-29 | P3 | Angiocrine Bioscience | NCT05181540 A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation | Hodgkin Lymphoma; Non Hodgkin Lymphoma | terminated | 130 |
| 2023-12-29 | P2 | OcuTerra Therapeutics, Inc. | NCT05409235 Nesvategrast (OTT166) in Diabetic Retinopathy (DR) | Diabetic Retinopathy | completed | 225 |
| 2023-12-29 est. | P2 | Inreda Diabetic B.V. | NCT05454709 A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System | Diabetes Mellitus, Type 1 | withdrawn | |
| 2023-12-30 | P1/P2 | Golden Biotechnology Corporation | NCT03310632 Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer | Pancreatic Neoplasm | completed | 55 |
| 2023-12-30 est. | P3 | Shanghai Henlius Biotech | NCT04033354 A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin | Squamous Non Small Cell Lung Cancer | unknown | 537 |
| 2023-12-30 est. | P2 | MedPacto, Inc. | NCT04064190 Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | Urothelial Carcinoma Recurrent; Advanced Urothelial Carcinoma | withdrawn | |
| 2023-12-30 est. | P2 | ImmuniMed Inc. | NCT04121169 Treatment of Mild-moderate Clostridium Difficile Infection (CDI) | Clostridium Difficile Infection (CDI) | unknown | 60 |
| 2023-12-30 | P2 | AgelessRx | NCT04488601 Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study | Aging | completed | 129 |
| 2023-12-30 est. | P3 | Hamad Medical Corporation | NCT04571879 Nebulized Lidocaine and Intranasal Midazolam for NGT Insertion in Children | Procedural Anxiety; Procedural Pain | unknown | 48 |
| 2023-12-30 | P3 | Mirati Therapeutics Inc. | NCT04685135 Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer | active not recruiting | 453 |
| 2023-12-30 | P3 | Checkpoint Therapeutics, Inc. | NCT04786964 Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC | Metastatic Non-squamous Non Small Cell Lung Cancer | terminated | 25 |
| 2023-12-30 est. | P2 | Reponex Pharmaceuticals A/S | NCT04823962 Effect of rhGM-CSF on the Healing of Venous Leg Ulcers | Venous Leg Ulcer | unknown | 6 |
| 2023-12-30 est. | P2 | PharmaTher Inc. | NCT04912115 Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia | Dyskinesias; Movement Disorders; Central Nervous System Diseases; Nervous System Diseases; Neurologi | suspended | 30 |
| 2023-12-30 | P1/P2 | WPD Pharmaceuticals Sp. z o.o. | NCT04915404 Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | Recurrent Glioblastoma Multiforme | terminated | 5 |
| 2023-12-30 est. | P1/P2 | SkinJect, Inc. | NCT04928222 Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) | Basal Cell Carcinoma | active not recruiting | 25 |
| 2023-12-30 | P1/P2 | Oticara Australia PTY LTD | NCT05220293 Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream | Chronic Rhinosinusitis (Diagnosis) | terminated | 2 |
| 2023-12-30 est. | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT05232149 A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia | Primary Immune Thrombocytopenia | unknown | 30 |
| 2023-12-30 est. | P2 | Blade Therapeutics | NCT05373914 RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | unknown | 200 |
| 2023-12-30 est. | P1/P2 | Maxinovel Pty., Ltd. | NCT05425602 A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors | Advanced / Metastatic Solid Tumors | unknown | 108 |
| 2023-12-30 | P2 | BioMimetix JV, LLC | NCT05491447 A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis | Atopic Dermatitis | terminated | 103 |
| 2023-12-30 est. | P2 | Shijiazhuang Yiling Pharmaceutical Co. Ltd | NCT05515393 A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke | Acute Ischemic Stroke | unknown | 420 |
| 2023-12-30 | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT05538195 Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors | Gastric Cancer; Colon Cancer; Rectal Cancer; Esophageal Cancer; Pancreatic Cancer | completed | 17 |
| 2023-12-30 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT05603039 A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | Advanced Liver Cancer | unknown | 80 |
| 2023-12-30 est. | P2 | Keymed Biosciences Co.Ltd | NCT05671432 The Study of CM326 in Moderate-to-severe Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis | unknown | 240 |
| 2023-12-30 | P3 | BRIM Biotechnology Inc. | NCT05695781 Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects. | Dry Eye Disease | completed | 740 |
| 2023-12-30 est. | P1/P2 | Suzhou Puhe Pharmaceutical Technology Co., LTD | NCT05767866 Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR | Treatment; Treatment Side Effects | unknown | 160 |
| 2023-12-30 | P2 | CureLab Oncology | NCT05979298 Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer | Ovarian Cancer; Platinum-resistant Ovarian Cancer | completed | 40 |
| 2023-12-30 | P3 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07028320 To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk | Postmenopausal Women With Osteoporosis | completed | 493 |
| 2023-12-31 est. | P1/P2 | Nanjing Legend Biotech Co. | NCT03090659 LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | Refractory or Relapsed Multiple Myeloma | unknown | 100 |
| 2023-12-31 est. | P1/P2 | NeuroGeneration | NCT03309514 Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease | Parkinson's Disease | withdrawn | |
| 2023-12-31 | P1/P2 | Agalimmune Ltd. | NCT03593226 Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour | Superficial, Palpable, Unresectable/Metastatic Solid Tumour | completed | 38 |
| 2023-12-31 | P1/P2 | BioMimetix JV, LLC | NCT03608020 A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy | Multiple Brain Metastases | terminated | 35 |
| 2023-12-31 est. | P2/P3 | Kartos Therapeutics, Inc. | NCT03662126 KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment | Primary Myelofibrosis (PMF); Post-Polycythemia Vera MF (Post-PV-MF); Post-Essential Thrombocythemia | unknown | 385 |
| 2023-12-31 | P2 | Igy Inc. | NCT03707730 A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease | Celiac Disease | completed | 161 |
| 2023-12-31 est. | P2 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | NCT03836352 Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid | Ovarian Cancer; Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Bladder Cancer; Microsatellite | active not recruiting | 184 |
| 2023-12-31 est. | P2 | Beijing Biostar Pharmaceuticals Co., Ltd. | NCT03906565 Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer | Advanced or Metastatic CRC | suspended | 30 |
| 2023-12-31 | P1/P2 | Buzzard Pharmaceuticals | NCT04121442 Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors | Solid Tumor, Adult | completed | 15 |
| 2023-12-31 | P2 | Revimmune | NCT04154826 Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease | Mycobacterium Infections, Nontuberculous | terminated | 8 |
| 2023-12-31 est. | P3 | Cerecin | NCT04187547 A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension | Alzheimer's Disease | withdrawn | |
| 2023-12-31 est. | P2 | Vivacelle Bio | NCT04257136 VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients | Septic Shock; Sepsis; Hypovolemia | unknown | 20 |
| 2023-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04265963 CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia | Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute | unknown | 45 |
| 2023-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04271410 CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-cell; Lymphoma, B-Cell; Leukemia, Lymphocytic | unknown | 80 |
| 2023-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04271800 Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | Leukemia; Lymphoma; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | unknown | 40 |
| 2023-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04272125 Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia | Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute | unknown | 40 |
| 2023-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04272151 Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | Multiple Myeloma; Multiple Myeloma in Relapse; Neoplasm, Plasma Cell | unknown | 40 |
| 2023-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04348643 Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | Solid Tumor; Lung Cancer; Colorectal Cancer; Liver Cancer; Pancreatic Cancer; Gastric Cancer; Breast | withdrawn | |
| 2023-12-31 | P2 | Alethia Biotherapeutics | NCT04364620 AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) | NSCLC Stage IV | completed | 35 |
| 2023-12-31 est. | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT04438044 A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL | PCNSL; Secondary Central Nervous System Lymphoma | unknown | 61 |
| 2023-12-31 est. | P2 | Sound Pharmaceuticals, Incorporated SOGP | NCT04484025 SPI-1005 Treatment in Moderate COVID-19 Patients | Covid19; Corona Virus Infection; Coronavirus; Coronavirus Infection | enrolling by invitation | 60 |
| 2023-12-31 est. | P2 | Minoryx Therapeutics, S.L. | NCT04528706 A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression | Cerebral Adrenoleukodystrophy | unknown | 13 |
| 2023-12-31 | P3 | Merck Sharp & Dohme LLC MRK | NCT04635423 Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064) | Warts, Genital; Neoplasms, Anal | completed | 1059 |
| 2023-12-31 | P1/P2 | Akeso | NCT04647344 A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV | completed | 46 |
| 2023-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04648475 Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | Leukemia, B-cell; Lymphoma, B-Cell | unknown | 40 |
| 2023-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04649983 CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | Leukemia, B-cell; Lymphoma, B-Cell | unknown | 40 |
| 2023-12-31 | P2 | Galecto Biotech AB | NCT04679870 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis | Myelofibrosis | active not recruiting | 21 |
| 2023-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04782193 a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | B Cell Lymphoma | unknown | 40 |
| 2023-12-31 | P1/P2 | Genfleet Therapeutics (Shanghai) Inc. | NCT04914286 A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Advanced Solid Tumor | completed | 148 |
| 2023-12-31 | P1/P2 | CicloMed LLC | NCT04956042 Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia | terminated | 18 |
| 2023-12-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05042375 A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | unknown | 450 |
| 2023-12-31 est. | P2 | Shandong New Time Pharmaceutical Co., LTD | NCT05178836 A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL | RR DLBCL; PD-1; CD20 | unknown | 62 |
| 2023-12-31 est. | P1/P2 | Mindful Diagnostics and Therapeutics, LLC | NCT05183516 Tdap and Biomarkers of Alzheimer's Disease | Alzheimer Disease, Late Onset | unknown | 50 |
| 2023-12-31 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT05193214 A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma | Sarcoma, Soft Tissue | unknown | 30 |
| 2023-12-31 est. | P2 | ES Therapeutics Australia Pty Ltd | NCT05234762 Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors | Tremor, Essential | unknown | 24 |
| 2023-12-31 | P3 | KalVista Pharmaceuticals, Ltd. | NCT05259917 A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult P | Hereditary Angioedema | completed | 136 |
| 2023-12-31 est. | P2 | Shanghai JMT-Bio Inc. | NCT05278338 Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis | Postmenopausal Osteoporosis | unknown | 200 |
| 2023-12-31 | P3 | Vaxine Pty Ltd | NCT05279456 A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen) | COVID-19 | completed | 39 |
| 2023-12-31 est. | P2 | United BioPharma UTHR | NCT05298215 A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous | Chronic Spontaneous Urticaria | unknown | 25 |
| 2023-12-31 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05334810 DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer | HER2-positive Breast Cancer | unknown | 191 |
| 2023-12-31 | P2 | TJ Biopharma Co., Ltd. | NCT05338580 Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors | First-line Non-small-cell Lung Cancer; First-line Urothelial Carcinoma; Second-line Urothelial Carci | withdrawn | |
| 2023-12-31 est. | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT05372120 A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations | Advanced Solid Tumor | unknown | 200 |
| 2023-12-31 | P2 | Genfleet Therapeutics (Shanghai) Inc. | NCT05386888 A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC | NSCLC, Stage III | completed | 65 |
| 2023-12-31 est. | P3 | Betta Pharmaceuticals Co., Ltd. | NCT05433480 A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer | Breast Cancer | unknown | 274 |
| 2023-12-31 est. | P1/P2 | Theratocular Biotek Co. | NCT05456724 A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension | Open Angle Glaucoma; Ocular Hypertension | unknown | 50 |
| 2023-12-31 est. | P2 | DermBiont, Inc. | NCT05493488 A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis | Tinea Pedis | unknown | 24 |
| 2023-12-31 est. | P2/P3 | Genencell Co. Ltd. | NCT05525182 Efficacy and Safety of ES16001 in Patients With COVID-19 | COVID-19 | unknown | 706 |
| 2023-12-31 est. | P2 | TruDiagnostic | NCT05535608 Targeting the Nine Hallmarks of Aging on DNA Methylation | Aging | unknown | 50 |
| 2023-12-31 | P3 | Vaxine Pty Ltd | NCT05542862 Booster Study of SpikoGen COVID-19 Vaccine | COVID-19 | completed | 81 |
| 2023-12-31 | P3 | PT Bio Farma | NCT05546502 Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children | Vaccine Reaction; Vaccine Adverse Reaction | completed | 1050 |
| 2023-12-31 | P2 | Shanghai Henlius Biotech | NCT05584137 Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC | Colorectal Cancer Metastatic | terminated | 2 |
| 2023-12-31 est. | P2 | Zhejiang Genfleet Therapeutics Co., Ltd. | NCT05618691 A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC) | Intermittent Claudication; Peripheral Artery Disease | withdrawn | |
| 2023-12-31 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05653180 IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer | Advanced Biliary Tract Cancer | unknown | 20 |
| 2023-12-31 est. | P2 | Attgeno AB | NCT05699486 A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery | Pulmonary Hypertension | unknown | 12 |
| 2023-12-31 est. | P1/P2 | Vac4All | NCT05776017 MSP3-CRM-Vac4All/ Alhydrogel® Vaccine | Malaria,Falciparum | unknown | 465 |
| 2023-12-31 | P2 | ZetrOZ, Inc. | NCT05882812 Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis | Osteo Arthritis Knee; Arthritis | completed | 200 |
| 2023-12-31 | P2 | Immuno Cure 3 Limited | NCT05904054 Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV) | COVID-19 | completed | 31 |
| 2023-12-31 est. | P3 | Biocad | NCT05986331 Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma | Melanoma (Skin) | unknown | 366 |
| 2023-12-31 est. | P2 | Simon Williamson Clinic | NCT06065722 Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy | Chemotherapy Induced Nausea and Vomiting | unknown | 100 |
| 2023-12-31 | P3 | NPO Petrovax | NCT06383819 Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19 | Post-Acute COVID-19 Syndrome; Lung Disease With Polymyositis; Fibrosis; Lung Diseases, Interstitial; | completed | 392 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.